Saturday, September 19, 2026

Private Credit Funds Hit Brakes on Withdrawals as Asset Sales Signal Portfolio Stress

Blue Owl halted quarterly withdrawals from its retail fund while New Mountain Finance sold assets at a discount, sending shares to 2020 lows. FS KKR Capital cut dividends as BDC managers defend valuations amid questions about mark-to-model pricing versus secondary market reality.

Private Credit Funds Hit Brakes on Withdrawals as Asset Sales Signal Portfolio Stress
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Blue Owl Capital suspended quarterly withdrawals from its retail private credit fund, marking the latest liquidity restriction in a sector facing questions about hidden losses. The move follows FS KKR Capital's dividend cut and New Mountain Finance's distressed asset sale that pushed shares to their lowest level since 2020.

New Mountain sold assets at a discount to book value, a transaction that exposed the gap between reported net asset values and actual market prices. Secondary market pricing for private credit positions is running below the mark-to-model valuations many funds use for quarterly reporting.

Bank of America rated Blue Owl a buy "amid misinformation," defensive language that suggests analysts are fielding client concerns about portfolio quality. The firm's withdrawal halt prevents investors from testing fund valuations with redemption requests.

Gladstone Capital management said they "feel better about non-accrual names than a year ago" despite challenging M&A valuations, an optimistic stance that contrasts with market signals. Non-accrual rates measure loans no longer generating interest income, a key credit quality metric for business development companies.

The convergence of withdrawal restrictions, dividend cuts, and below-NAV asset sales suggests private credit portfolios face deterioration masked by quarterly valuation methods. Funds typically mark holdings to internal models rather than observable market prices, creating potential gaps when forced to transact.

European insurers are distancing themselves from private credit exposure. AXA CEO Thomas Buberl noted the firm's exposure sits "far below that of rivals," while Allianz's Claire-Marie Coste-Lepoutre said she remains "very comfortable" with current positions. The comments suggest institutional investors see reason for caution.

Withdrawal restrictions and asset sales at distressed prices provide the clearest test of private credit valuations. When funds must transact rather than mark to model, the difference between reported NAVs and actual prices becomes visible. The timing of Blue Owl's withdrawal halt before quarter-end could delay potential write-downs that secondary market activity might otherwise force.

Investors watching for credit stress signals should track covenant violation disclosures in BDC quarterly filings, changes in independent valuation firms, and correlation between withdrawal timing and subsequent portfolio adjustments.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com